Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Affiliations

• ¹ Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
• ² Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN.
• ³ Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
• ⁴ Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
• ⁵ Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
• ⁶ University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
• ⁷ Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL.
• ⁸ Division of Hematology and Oncology, Department of Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT.
• ⁹ Winship Cancer Institute of Emory University, Atlanta, GA.
• ¹⁰ David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.
• ¹¹ University of California, San Francisco, San Francisco, CA.
• ¹² Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.
• ¹³ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
• ¹⁴ University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA.
• ¹⁵ Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
• ¹⁶ The Ohio State University, Columbus, OH.
• ¹⁷ University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
• ¹⁸ Biopharmatech Consulting, Inc., Leesburg, VA.
• ¹⁹ Leukemia and Lymphoma Society, White Plains, NY.
• ²⁰ Department of Medicine, University of Cincinnati, Cincinnati, OH.
• ²¹ Division of Hematology-Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL.